SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc. ($MTEX) is currently trending with strong community interest, fueled by its notably low public float and increasing buying momentum. Traders are actively anticipating a significant breakout and a potential short squeeze, eyeing key price levels as volume continues to build.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is commanding market attention as a critical year-end deadline approaches for its Austin robotaxi service to operate without safety monitors, serving as a pivotal test for its AI and autonomous driving ambitions. The community is intensely divided; bulls foresee a significant rebound driven by anticipated breakthroughs in FSD and robotics, while bears highlight concerns over slowing EV demand, recent battery supply contract cuts, and a valuation heavily reliant on unproven future promises. With upcoming delivery reports also on the horizon, the market's focus remains squarely on these near-term developments to gauge the company's trajectory beyond its traditional automotive segment.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending with high anticipation for the January 31, 2026 PDUFA date of its needle-free Anaphylm oral epinephrine film, a key catalyst significantly de-risked by the FDA waiving an Advisory Committee meeting. The community is expressing strong conviction for approval, highlighting Anaphylm's potential to be a market-dominant, game-changing alternative for severe allergic reactions due to its convenience. Despite active debate with short sellers and market fluctuations, many investors are looking towards significant post-approval price appreciation and future growth.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid a dual narrative: China's sanctions, perceived by many as validation of its strategic importance in defense, and the imminent U.S. ban on foreign-made drones. The community is actively discussing how these developments, coupled with anticipated increases in defense budgets for U.S.-made small drones and unmanned surface vessels, could position the company for significant contract awards, despite past concerns over management's communication and tangible revenue delivery.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 trial data showing an 80% reduction in breast cancer recurrence, alongside a significant show of insider confidence with the Board extending share lock-ups until September 2026. This news has intensified community discussions around a potential short squeeze, given the stock's extremely low float and high cost to borrow, as investors anticipate substantial upside for this undervalued immunotherapy company.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is currently a hot topic after discontinuing its RAMP 203 trial to focus on the promising VS-7375 program, a strategic pivot that followed strong Q3 revenue beats. However, a recent $90 million public offering has sparked considerable frustration and debate among investors, many of whom feel betrayed by the dilution despite the company's stated financial position. This has led to accusations of market manipulation and amplified concerns about short selling within a volatile biotech sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is actively trending following a significant pullback from recent highs, with community discussion centered on whether this sharp drop is a healthy consolidation or a market-maker-driven "rugpull" fueled by increased margin requirements. While many view it as a buying opportunity in a broader context of a weakening dollar and persistent inflation concerns, others express caution, debating the sustainability of the rally and the potential for further volatility across precious metals.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending as discussions intensify around its near-term regulatory decision for Relacorilant for Cushing's syndrome and the promising trial outcomes for its ovarian cancer and ALS programs. The community anticipates these pipeline advancements will unlock substantial future revenue, positioning the company for significant growth and prompting speculation about a potential short squeeze given its high short interest. This outlook is further supported by updated analyst price targets reflecting optimism about Corcept's expanding therapeutic impact.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending amidst high anticipation for multiple regulatory catalysts, including upcoming FDA decisions for Tradipitant for motion sickness and Bysanti. The community is actively discussing recent positive Phase 2 data showing Tradipitant's efficacy in mitigating GLP-1 induced nausea, with many speculating this could unlock a massive market and lead to significant stock re-rating or a potential buyout.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) experienced a sharp pullback following the CME Group's increase in margin requirements for silver futures, triggering forced liquidations. This move has ignited intense community debate, with many investors citing market manipulation and a disconnect between paper and physical silver prices, particularly in light of impending Chinese export restrictions. Despite the volatility, many bulls are calling this a buying opportunity due to perceived supply shortages and increasing industrial demand, while others anticipate further declines and lament potential 'bag holding.'

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Caterpillar’s E&T segment is likely a core driver to the next EPS cycle: BofA

Investing.com -- Bank of America analysts say Caterpillar’s Energy&Transportation (E&T) division is set to become the company’s key growth engine, citing strong multi-year tailwinds from data centers, power generation, and gas pipelines.

UBS upgrades Caterpillar as trade risks ease, but macro uncertainty remains

Investing.com -- UBS upgraded  Caterpillar  (NYSE:CAT) to Neutral from Sell in a note Friday, raising its price target for the stock to $357 from $272 a share. 

Caterpillar raised at Baird as ’fundamentals stabilizing’

Investing.com -- Baird upgraded  Caterpillar  (NYSE:CAT) to Outperform with a $395 price target on Tuesday, pointing to improving fundamentals, easing trade tensions, and signs of a potential earnings recovery beginning in late 2025.

Caterpillar raised at Baird as negative catalysts now baked into expectations

Investing.com -- Baird upgraded  Caterpillar  (NYSE:CAT) to Neutral from Underperform on Thursday, raising its price target for the stock to $309 from $300 a share. 

Wall Street sees strategic continuity as Caterpillar names Creed CEO

Investing.com -- Caterpillar’s appointment of insider Joe Creed as its next chief executive, was dubbed a “well-telegraphed transition” by Wall Street that ensures strategic continuity at a pivotal time for the construction and machinery giant.

UBS downgrades Caterpillar as tariff and macro woes to drag earnings down

Investing.com -- UBS downgraded  Caterpillar  Inc (NYSE:CAT) to Sell from Buy and slashed its price target to $243 from $385, warning that macroeconomic risks linked to tariffs and weakening global demand are not yet fully reflected in the stock.Caterpillar, often viewed as a bellwether for the broader industrial economy, is vulnerable to a slowdown in key end markets such as construction, oil&gas, and mining. These sectors could weaken further as uncertainty mounts over U.S. trade policy and global growth prospects dim.

UBS upgrades Caterpillar stock to Neutral on lowered investor expectations

Investing.com -- UBS has upgraded  Caterpillar  (NYSE:CAT) shares from Sell to Neutral, highlighting a reset in investor expectations following two consecutive quarterly EBIT misses.

Microsoft, UPS, American Airlines fall premarket; Tesla, Meta Platforms rise

Investing.com -- US stock futures rose Thursday after the Federal Reserve maintained interest rates unchanged, with the quarterly earnings season in full flow.

Caterpillar shares fall as Q4 revenue misses estimates

Investing.com -- Caterpillar Inc. reported fourth-quarter earnings that beat analyst expectations, but revenue fell short of estimates, sending shares down 3.64% in early trading.

Cardtronics is specializing in managing self-service financial kiosks, providing the physical conduit through which consumers interact with their funds and financial institutions while moving about the real world of everyday life. Their focus is on providing the management and operational expertise used by the worldâ??s highest-profile and most influential banking and retail brands to provide remote financial access to their customers.

CATM
Cardtronics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CATM News

CATMCardtronics Inc.